(0.16%) 5 139.75 points
(0.11%) 38 482 points
(0.25%) 17 891 points
(-0.19%) $83.69
(0.99%) $1.942
(0.28%) $2 353.80
(0.56%) $27.69
(1.71%) $937.85
(-0.18%) $0.933
(-0.31%) $10.99
(-0.29%) $0.798
(1.20%) $92.98
Live Chart Being Loaded With Signals
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments...
Stats | |
---|---|
今日成交量 | 94 833.00 |
平均成交量 | 689 294 |
市值 | 408.25B |
EPS | KRW0 ( 2024-04-22 ) |
下一个收益日期 | ( KRW0 ) 2024-05-13 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW7.24 (0.12%) |
音量 相关性
Bukwang Pharmaceutical 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Bukwang Pharmaceutical 相关性 - 货币/商品
Bukwang Pharmaceutical 财务报表
Annual | 2023 |
营收: | KRW125.93B |
毛利润: | KRW50.05B (39.74 %) |
EPS: | KRW-457.67 |
FY | 2023 |
营收: | KRW125.93B |
毛利润: | KRW50.05B (39.74 %) |
EPS: | KRW-457.67 |
FY | 2022 |
营收: | KRW190.91B |
毛利润: | KRW79.43B (41.61 %) |
EPS: | KRW-62.07 |
FY | 2021 |
营收: | KRW182.49B |
毛利润: | KRW75.76B (41.51 %) |
EPS: | KRW-8.74 |
Financial Reports:
No articles found.
Bukwang Pharmaceutical
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。